Frequency and Types of Healthcare Encounters in the Week Preceding a Sepsis Hospitalization: A Systematic Review von Flannery, Alexander H, Venn, Chad M, Gusovsky, Amanda, Henderson, Stephanie, Kiser, Adam S, Prescott, Hallie C, Rhee, Chanu, Delcher, Chris, Morris, Peter E

Volltext

Efficacy of Hypomethylating Agents with Venetoclax in TP53mut AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Back in JAK - Real-World Analysis of JAKmut AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

IDH1/2 mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Efficacy of Hypomethylating Agents with Venetoclax in TP53 mut AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

IDH1/2mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Back in JAK - Real-World Analysis of JAK mut AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC von Bouligny, Ian M., Murray, Graeme, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Maher, Keri

Volltext

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia von Bouligny, Ian M., Murray, Graeme, Doyel, Michael, Patel, Tilak, Boron, Josh, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Wages, Nolan A., Grant, Steven, Maher, Keri R.

Volltext

Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia von Bouligny, Ian M., Murray, Graeme, Ho, Thuy, Doyel, Michael, Patel, Tilak, Boron, Josh, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Zacholski, Kyle, Venn, Chad, Wages, Nolan A., Grant, Steven, Maher, Keri R.

Volltext

Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia von Bouligny, Ian M., Murray, Graeme, Doyel, Michael, Patel, Tilak, Boron, Josh, Tran, Valerie, Gor, Juhi, Hang, Yiwei, Alnimer, Yanal, Ho, Thuy, Zacholski, Kyle, Venn, Chad, Wages, Nolan A., Grant, Steven, Maher, Keri R.

Volltext